Pliant Therapeutics, Inc. (PLRX) AI Stock Analysis

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to advancing novel therapies for fibrosis and related diseases. Its lead candidate, PLN-74809, is an oral small-molecule dual selective inhibitor targeting integrins, currently evaluated in three Phase 2a clinical trials. The company is also advancing PLN-1474, a small-molecule selective inhibitor targeting integrins that has completed Phase 1 trials for liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Additionally, Pliant is progressing two preclinical integrin-based programs focusing on oncology and muscular dystrophies.

Annual revenue declined from $57.1M in FY2019 to $1.6M in FY2023, reflecting a 4-year revenue CAGR of -59.2%. Net losses widened over this period from -$631,000 in FY2019 to -$161.3M in FY2023, as research and development expenses climbed from $47.4M to $127.8M. For the trailing twelve months ending June 30, 2026, revenue was $0, with quarterly revenue growth of -100.0% year-over-year. Diluted EPS over the trailing twelve months was -$1.50, alongside a return on equity of -50.3% and a return on assets of -23.3%.

As of June 30, 2026, Pliant Therapeutics held $158.1M in cash and short-term investments against total debt of $28.7M, resulting in net cash of $129.4M. Its current ratio stood at 9.90, and debt-to-equity was 0.20, supported by shareholders' equity of $146.9M and total assets of $189.9M. In FY2025, capital expenditures totaled $374,000. Over the past five years, the company's share count expanded by 71.9%.

Pliant Therapeutics trades at a market cap of $55.7M and an enterprise value of -$60.0M, with a price-to-book ratio of 0.5x. In comparison, the median of its US-listed Healthcare peers trades at a trailing P/E of 24.6x, a forward P/E of 17.3x, and a price-to-sales multiple of 4.1x. Over the past year, the stock declined 45.5%, while the S&P 500 (SPY) returned 16.8%. Over a 5-year period, PLRX returned -95.0% compared to an 83.0% gain for the S&P 500.

Wall Street analyst coverage consists of 0 Strong Buy, 0 Buy, 3 Hold, and 1 Sell ratings. The mean price target is $2.00, representing a 122.2% premium over the last close of $0.90. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $0 and an EPS of -$1.43. For the following fiscal year, analysts estimate revenue of $0 and an EPS of -$1.28. The company beat EPS estimates in 3 of the last 4 quarters, with its next earnings date scheduled for November 5, 2026.

This page is an AI-written research summary of Pliant Therapeutics, Inc. (PLRX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PLRX income statement, PLRX balance sheet, PLRX key metrics, PLRX analyst forecast, PLRX chart. See the PLRX stock overview for the latest quote and news.